124 completed, 13 terminated, 7 unknown, 4 withdrawn. 40 Phase 3, 39 Phase 4, 35 Phase 1, 26 Phase 2, 7 Not applicable.
Follow this drug Literature Review of Atazanavir Sulfate trials Research Report on Atazanavir Sulfate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection Drug: NA-831, NA-831 and Atazanavir, NA-831and Dexamethasone - Coronavirus Infection, Severe Acute Respiratory Infection | Phase 2 / Phase 3 | Unknown | Biomed Industries, Inc. | 525 | 2022-06-15 | 2022-02-16 |
| A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions Atazanavir, Cobicistat, Atazanavir/Cobicistat Mini-tablet - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 42 | 2022-05-13 | 2022-10-31 |
| Antiviral Agents Against COVID-19 Infection Atazanavir, Daclatasvir 60 mg, Sofusbuvir + Daclastavir 60 mg - COVID-19 | Phase 2 / Phase 3 | Completed | Hospital do Coracao | 256 | 2021-02-15 | 2024-03-22 |
| The Nitazoxanide Plus Atazanavir for COVID-19 Study Nitazoxanide and atazanavir/ritonavir, Standard of Care - Covid-19 | Phase 2 | Terminated | Obafemi Awolowo University | 57 | 2020-10-09 | 2022-03-02 |
| A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time Atazanavir/Cobicistat, Reyataz Atazanavir, Cobicistat - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 34 | 2020-02-26 | 2021-11-23 |
| Pharmacokinetics of Atazanavir in Special Populations Atazanavir 300mg/ Ritonavir 100 mg once daily, Atazanavir 250 mg / ritonavir 80 mg - HIV/AIDS, Tuberculosis | Completed | University of Liverpool | 32 | 2019-09-02 | 2023-05-09 | |
| Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials Belinostat, Atazanavir - Solid Tumor, Hematological Malignancies | Phase 1 | Completed | Acrotech Biopharma Inc. | 8 | 2019-08-05 | 2023-05-03 |
| Population Pharmacokinetics of Antiretroviral in Children Dolutegravir, Raltegravir, Rilpivirine - Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed | Completed | Assistance Publique - Hôpitaux de Paris | 65 | 2017-06-16 | 2026-04-03 | |
| Pharmacokinetic Effect of Evotaz/Microgynon Co-administration Microgynon 30®, Evotaz® - HIV | Phase 1 | Terminated | St Stephens Aids Trust | 13 | 2016-07-01 | 2018-01-02 |
| Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women E/C/F/TAF, E/C/F/TDF, ATV - HIV-1 Infection | Phase 3 | Completed | Gilead Sciences | 472 | 2016-02-19 | 2020-03-04 |
| Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD) - HIV Infection | Phase 3 | Withdrawn | University of Turin, Italy | 2016-01-01 | 2020-11-06 | |
| A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat Daclatasvir, Atazanavir, Ritonavir - Hepatitis C, HIV | Phase 1 | Completed | Radboud University Medical Center | 16 | 2015-11-01 | 2020-12-07 |
| SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat Evotaz, Rezolsta - HIV | Phase 1 | Completed | St Stephens Aids Trust | 16 | 2015-11-01 | 2016-03-22 |
| A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg - HIV-1 Infection | Phase 2 | Completed | Castagna Antonella | 10 | 2015-09-01 | 2024-02-13 |
| Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen Atazanavir, Dolutegravir, Lamivudine - HIV-1 Infection | Phase 2 | Terminated | Radboud University Medical Center | 9 | 2015-08-01 | 2020-12-07 |
| A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 1 | Completed | Hoffmann-La Roche | 85 | 2015-07-22 | 2021-04-02 |
| Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults BMS-955176, Atazanavir (ATV), Ritonavir (RTV) - HIV Infections | Phase 2 | Terminated | ViiV Healthcare | 86 | 2015-07-08 | 2018-08-20 |
| Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients Atazanavir 200 mg/r - HIV-1 Infection | Phase 2 | Completed | Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | 90 | 2015-06-01 | 2018-08-21 |
| HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen Dolutegravir, PI, 2 NRTI - HIV-1 | Phase 4 | Completed | Hospital Universitari Vall d'Hebron Research Institute | 44 | 2015-06-01 | 2017-06-14 |
| Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults STB, TVD, ATR - HIV-1 Infection | Phase 4 | Completed | Gilead Sciences | 72 | 2014-12-15 | 2018-01-03 |
Showing 20 of 150. Sign in to see all of them.
HIV Infections (89) · Acquired Immunodeficiency Syndrome (26) · Infections (7) · COVID-19 (3) · Coronavirus Infections (2) · Hepatitis C (2) · Hyperlipidemias (2) · Lipodystrophy (2) · Severe Acute Respiratory Syndrome (2) · Tuberculosis (2) · AIDS Dementia Complex (1) · Atherosclerosis (1) · Bone Diseases, Metabolic (1) · Cognitive Dysfunction (1) · Coinfection (1)
Bristol-Myers Squibb (43) · Gilead Sciences (10) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · ViiV Healthcare (6) · Radboud University Medical Center (5) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (4) · Boehringer Ingelheim (4) · Kirby Institute (4) · Hoffmann-La Roche (3) · ANRS, Emerging Infectious Diseases (2) · Brigham and Women's Hospital (2) · Catholic University of the Sacred Heart (2) · French National Agency for Research on AIDS and Viral Hepatitis (2) · Germans Trias i Pujol Hospital (2) · GlaxoSmithKline (2)
United States (95) · Puerto Rico (24) · France (23) · United Kingdom (22) · Italy (21) · Spain (20) · Thailand (20) · Canada (18) · Mexico (18) · Argentina (17) · South Africa (17) · Germany (16) · Brazil (13) · Russia (11) · Netherlands (10)
Jennifer R. King, PharmD (2) · Marta Boffito (2) · Ram Yogev, MD (2) · Adriano Lazzarin, Prof (1) · Adriano Lazzarin, Professor (1) · Alan Winston, MD (1) · Alexandra Calmy (1) · Andrea De Luca, MD (1) · Andrew R Zolopa (1) · Bonaventura Clotet, MD, PhD (1)
PMID 24979445, PMID 33901188, PMID 25904376, PMID 26797215, PMID 32829410, PMID 35179037, PMID 38160309, PMID 14669723, PMID 15115831, PMID 15155205, PMID 15199325, PMID 16287792, PMID 16470119, PMID 16905783, PMID 16905786, PMID 16988514, PMID 17310819, PMID 17357053, PMID 17576825, PMID 18193496, PMID 18366444, PMID 18636958, PMID 18653575, PMID 18795962, PMID 18989231, PMID 19118378, PMID 19191590, PMID 19358725, PMID 19710077, PMID 19906626, PMID 19952143, PMID 19952712, PMID 20002783, PMID 20102271, PMID 20121419, PMID 20146627, PMID 20632458, PMID 20735258, PMID 20827162, PMID 20939732, PMID 20961784, PMID 21148235, PMID 21148251, PMID 21283017, PMID 21320923, PMID 21329725, PMID 21470045, PMID 21499794, PMID 21555816, PMID 21569187
2009 (6), U01AI068636 (4), 2014 (2), K23AI074390 (2), K24AI051966 (2), 2004 (1), 2005 (1), 2008 (1), K23AI070078 (1), K23AI077355 (1), K23AI093156 (1), R01DA024982 (1), R01HL072711 (1), R01MH058076 (1), R03AI068438 (1)